Ibritumomab tiuxetan plus rituximab as initial therapy for patients with high tumor burden, indolent histology non-Hodgkin's lymphoma.

Trial Profile

Ibritumomab tiuxetan plus rituximab as initial therapy for patients with high tumor burden, indolent histology non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Planned Eed date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 06 Jun 2011 Planned End Date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top